Board of Directors

  • Tim Mayleben

    President and Chief Executive Officer

    Tim M. Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior to joining Esperion, Tim was President, CEO and a Director of Aastrom Biosciences, Inc. (NASDAQ: ASTM). Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including DeNovo Sciences, Kaléo Pharma, Lycera Corporation and Marinus Pharmaceuticals. Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

  • Roger Newton, PhD, FAHA

    Executive Chairman and Chief Scientific Officer

    Roger S. Newton, PhD, FAHA, is founder, Executive Chairman and Chief Scientific Officer of Esperion and is a fellow of the American Heart Association. Prior to founding Esperion in 2008, Roger was Senior Vice President, Pfizer Global R&D from 2004 to 2008. Previously, Roger was Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004. Prior to founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1998. Roger is a director of a number of life science companies including Juventas Therapeutics, Inc. and Rubicon Genomics, Inc. and is also a member of the Technology Advisory Boards for Arboretum Ventures and Metagenics, Inc. Roger earned a PhD in Nutrition from the University of California, Davis, an M.S. in Nutritional Biochemistry from the University of Connecticut, and a BS in Biology from Lafayette College.

  • Patrick Enright

    Managing Director, Longitude Capital Management Co., LLC

    Patrick Enright has served as a member of our board of directors since April 2013. Patrick is a founder of Longitude Capital Management Co., LLC, a venture capital firm focused on investments in biotechnology, and has served as its Managing Director since 2007. From 2002 through 2006, Patrick was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, Patrick was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately held and publicly traded biotechnology companies. Patrick is a director of a number of companies including Corcept Therapeutics, Inc. (NASDAQ: CORT) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Patrick earned an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.

  • Dov Goldstein, MD

    Partner, Aisling Capital

    Dov Goldstein, MD has served as a member of our board of directors since April 2008. He has been a partner at Aisling Capital, a private investment firm, since 2008. From 2006 to 2008, Dov was a Principal at Aisling Capital. From 2003 to 2005, Dov was Chief Financial Officer of Vicuron Pharmaceuticals, Inc. until its acquisition by Pfizer. Prior to that, Dov was an Executive Vice President of Vicuron Pharmaceuticals, Inc. Previously, he was Director of Venture Analysis at HealthCare Ventures. Dov is a director of a number of companies including ADMA Biologics, Inc. and Cempra Pharmaceuticals, Inc. (NASDAQ: CEMP). Dov earned a BS in biology from Stanford University, an MD from the Yale School of Medicine and an MBA from the Columbia Business School.

  • Antonio Gotto, Jr., MD, DPhil

    Dean Emeritus & Co-Chair of Board of Overseers, Weill Cornell Medical College

    Antonio M. Gotto, Jr., MD, DPhil was appointed to our board of directors in January 2014.  Antonio is Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University.  From January 1997 to December 2011, he served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University.  Previously, Antonio served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital.  Antonio currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.  He is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association.  Antonio holds a BA degree from Vanderbilt University, a DPhil degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an MD degree from Vanderbilt University School of Medicine.  Antonio completed his residency training at Massachusetts General Hospital in Boston, Massachusetts.  He is also a member of the Board of Directors of Aegerion Pharmaceuticals, Inc.

  • Dan Janney

    Managing Director, Alta Partners

    Dan Janney has served as a member of our board of directors since November 2012. Dan is a managing director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, Dan was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. He is a director of a number of companies including Alba Therapeutics Corporation, DiscoveRx Corporation, Lithera, Inc., Prolacta Bioscience, Inc. and ViroBay, Inc. Dan earned a BA of Arts in History from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.

  • Mark McGovern, MD, FACC, FACP

    Former Executive Vice President, Medical Affairs, & Chief Medical Officer, Kos Pharmaceuticals

    Mark E. McGovern, MD, FACC, FACP was appointed to our board of directors in February 2014.  Mark is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies. His experience includes 11 years at Bristol-Myers Squibb, where Mark was responsible for the clinical development of pravastatin (Pravachol®), in particular the programs for atherosclerosis regression and coronary heart disease prevention, including the WOSCOPS (West of Scotland Coronary Prevention Study), CARE(Cholesterol and Recurrent Events), and LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trials. He subsequently spent 10 years at Kos Pharmaceuticals, where he last served as executive vice president, medical affairs, and chief medical officer. During his career at Kos, Mark oversaw the phase IV trials of extended-release niacin (Niaspan®), and the registration programs for the first combination lipid therapies, niacin extended-release/lovastatin (Advicor®) and niacin extended release/simvastatin (Simcor®).  He currently serves as a consultant to the pharmaceutical industry for cardiovascular and atherosclerosis drug development. Mark earned his bachelor’s degree summa cum laude from Princeton University and his medical degree from the University of Vermont.  Mark is a Fellow of the American College of Cardiology and the American College of Physicians. He has published extensively on lipid management and its role in the treatment of coronary heart disease.

  • Gilbert Omenn, MD, PhD

    Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, University of Michigan

    Gilbert S. Omenn, MD, PhD, was appointed to our board of directors in June 2014.  Gil is Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, and Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He serves on the Scientific Management Review Board of the National Institute of Health (NIH) and the Community Preventive Services Task Force of the Centers for Disease Control and Prevention (CDC). Previously, Gil served as Chief Executive Officer of the University of Michigan Health System and Executive Vice President of the University of Michigan for Medical Affairs. He was Professor of Medicine and of Environmental Health, and Dean of the School of Public Health and Community Medicine, at the University of Washington. Gil was a member of the intramural program of NIH in the Anfinsen Lab and was a Howard Hughes Investigator with NIH grants spanning four decades. He served previously on the National Cancer Advisory Board, NIH Heart, Lung and Blood Institute Advisory Council, Society of Fellows for the NIH National Center for Minority Health and Health Disparities and on the Director’s Advisory Committee for the CDC. Gil earned his Bachelor’s degree summa cum laude from Princeton University, his medical degree magna cum laude from Harvard Medical School, and his PhD in genetics from the University of Washington. Previously, Gil has been a member of the board of directors for Amgen Inc. and Rohm & Haas Company.

  • Nicole Vitullo

    Director, Domain Associates, LLC

    Nicole Vitullo has served as a member of our board of directors since April 2008. Nicole joined Domain Associates, LLC, a venture capital firm with an exclusive focus on life sciences, in 1999, and became a Partner in 2004. From 1992-1999, Nicole was Senior Vice President at Rothschild Asset Management, Inc. Nicole is a director of a number of companies including Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Durata Therapeutics, Inc. (NASDAQ: DRTX), Marinus Pharmaceuticals, Inc. and VentiRx Pharmaceuticals, Inc. Nicole earned a BA and an MBA from the University of Rochester.